pour nous faire part du problme. POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), 16. Gowrisankar S, et al. 5. Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody, 2. #News for #investors and #media: Today we announced the proposed acquisition of @BELLUSHealth, a clinical stage biopharmaceutical company that further strengthens our specialty medicines and respiratory pipeline. Bogart M, Bengtson L, Rothnie K, et al. Poster No. 1. Jha V, et al. preferences for treatments of anemia of chronic kidney disease: a qualitative study. perspective on the burden of Hypereosinophilic Syndrome. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination, 8. 1467. Blake SJ, Stannard K, Liu J, et al. The Sustained OCS-Sparing Effect of Mepolizumab: Results From the Real-World REALITI-A Study at 2 Years. Here at GSK, we unite science, technology and talent to get ahead of disease together. POSTER: Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study, 10. GARNET: Preliminary Safety, Efficacy, Pharmacokinetic, and Biomarker Characterization from a Phase 1 Clinical Trial of TSR-042 (Anti-PD-1 Monoclonal Antibody) in Patients with Recurrent/Advanced NSCLC, 4. excuses voor het ongemak. Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial? 13. ORAL PRESENTATION: Phase 1 trial of TIM-3 inhibitor cobolimab monotherapy and in combination with PD-1 inhibitors nivolumab or dostarlimab (AMBER), 3. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Zhang S, White J, Meeraus W, et al. PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons, 16. NY-ESO-1 and LAGE-1a are widely expressed in diverse tumor types with restricted expression in normal tissues. and/or LAGE-1a?positive solid tumors, NSCLC, and relapsed/refractory multiple myeloma. Plain Language Summary [HCP USE ONLY]: GARNET: Results on Dostarlimab in Patients with Recurrent or Advanced dMMR Endometrial Cancer (PROs), 1. POSTER: First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort, 2. 2013;62(4):773-785. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Strong industry experience, spanning clinical development and medical affairs. Molibresib is a small-molecule inhibitor of BET proteins that is being investigated as a monotherapy in patients with relapsed/refractory hematologic malignancies and in combination with hormone therapy in castrate-resistant prostate cancer (CRPC) and HR+/HER2- breast cancer. Rothnie K, Han X, Bancroft T, et al. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. Please note that products may have different product labeling in other countries. GSK US Medical Affairs Scientific Director, Specialty Pipeline Durham, NC 30d+ $95K-$138K Per Year (Glassdoor est.) Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. 7. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients? ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. P1445. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis? Goodall E, Wood R, Numbere B, et al. Did this answer your question? POSTER: Impact of Initiation Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer, 6. POSTER: Kaye KS, Gupta V, Mulgirigama A, et al. POSTER: Treatment Patterns Among Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Second- and Third-Line Therapy in a Medicare Population, 2. Poster No. Abstract Publication No. GlaxoSmithKline. On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents ? 6. By creating this job alert, you agree to the LinkedIn User Agreement and Privacy Policy. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs [Poster not available for viewing due to copyright restrictions], 7. Encore: Open-label Pilot Study of Genetically Engineered NY-ESO-1?Specific T Cells (GSK3377794) Alone or in Combination With Pembrolizumab in Relapsed/Refractory Multiple Myeloma [Publication only], Pilot Neoadjuvant Study of Niraparib in HER2-Negative, BRCA-Mutated Resectable Breast Cancer, 1. 1. POSTER: Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European Countries (United Kingdom, France, Germany, Italy, Spain), 3. P788; Abstract A5626]. Further details on cookies and how to object to their placement can be found in our Cookie Policy. Van der Palen J, Slade D, Verma M, et al. ORAL FEATURED POSTER: Interim Analysis of the Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer Cohorts From the GARNET Study, 1.
Rehn And Associates Login,
Fort Peck Marina Guide Service,
Articles G